338-OR: Evaluation of the Spectrum Training Program for Real-Time Continuous Glucose Monitoring: A Multicenter Prospective Study in 120 Adults with Type 1 Diabetes
Authors: FRECKMANN GUIDO , SCHLUETER SANDRA , WINTERGERST PETER , HEINEMANN LUTZ , RÜCKERT TOBIAS , HINZ ANDREA , WERNSING MARITA , THIENEL FLORIAN , BIESTER TORBEN , BLANCKENBURG PHILIPP VON , KEUTHAGE WINFRIED , ZIEGLER RALPH , MARTIN EKKEHARD , HOLDER MARTIN , DEISS DOROTHEE , BUCHAL GEBHARD , DEN BOOM LOUISA VAN , LANGE KARIN 
Published: June 2020

Comprehensive knowledge, specific skills, and data-analysis competences are prerequisites of successful use of continuous glucose monitoring systems (CGM). SPECTRUM is a structured and manufacturer-independent training-program for real time CGM (rtCGM) comprising one web-based introduction and six modules (each 90 minutes) of face-to-face group sessions.

SPECTRUM was evaluated longitudinally among adults with type 1 diabetes from 10 diabetes centers. Outcome parameters were rtCGM-knowledge and -skills (rtCGM-Profi-Check), satisfaction with the course, technology acceptance and metabolic control. Initially 120 participants with type 1 diabetes were included (mean age 42.4±13.4 years, diabetes duration 21.6±11.6 years, 56% female, mean HbA1c 7.70±1.34%). Data were collected at study entry, after the final group session, and at 6 months follow-up. The study was completed by 108 patients (10% dropped out, mainly due to scheduling problems).

After training rtCGM knowledge (scale 0-40) improved by 43% (from 21.2±7.6 to 30.4±4.5; p&lt;0.001) and persisted until 6 months follow-up (29.6±4.6). After 6 months HbA1c decreased to 7.58±1.32% (p=0.036). On a scale from 0-14, practical skills were 13.1±1.3 after the program. Satisfaction with SPECTRUM was 1.4±0.5 (1 is good - 6 is bad). Satisfaction with the rtCGM system was 4.2±0.5 (scale from 1 (low) to 5 (high)) and acceptance of the rtCGM system was 87.6±8.2 (scale from 14 (low) to 98 (high)) after the training and 87.0±9.7 at follow up. This indicates a high acceptance, positive attitude, and intension to use rtCGM continuously.

SPECTRUM was shown to be effective in increasing the knowledge and skills about rtCGM in adults with type 1 diabetes. The effect was sustainable and independent from diabetes center and rtCGM-system used. Training participants showed an improvement in glycemic control and improved satisfaction and acceptance of rtCGM.

Disclosure

G. Freckmann: Advisory Panel; Self; Abbott, Sensile Medical AG. Consultant; Self; Beurer, iSens, Metronom Health, Pharmasens, Profusa, Inc., Roche Diabetes Care. Speaker’s Bureau; Self; Novo Nordisk A/S. S. Schlueter: Advisory Panel; Self; A. Menarini Diagnostics, Abbott. Consultant; Self; Roche Diabetes Care. Speaker’s Bureau; Self; Ascensia Diabetes Care, AstraZeneca, Berlin-Chemie AG, Dexcom, Inc., Medtronic, Merck Sharp & Dohme Corp., Novo Nordisk A/S, Roche Diabetes Care, Sanofi-Aventis Deutschland GmbH, Ypsomed AG. Other Relationship; Self; Springer Publishing Company, Verlag Kirchheim & Co. GmbH. P. Wintergerst: None. L. Heinemann: Consultant; Self; Becton, Dickinson and Company, LifeCare, Inc., Roche Diabetes Care. Stock/Shareholder; Self; Profil Institute for Clinical Research. T. Rückert: None. A. Hinz: Research Support; Self; Institut for Diabetestechnologie Ulm, Novo Nordisk A/S. Speaker’s Bureau; Self; AstraZeneca, Berlin-Chemie AG, Eli Lilly and Company. M. Wernsing: Advisory Panel; Self; Abbott. Research Support; Self; Roche Diabetes Care. F. Thienel: Research Support; Self; Roche Diabetes Care. Speaker’s Bureau; Self; Abbott. T. Biester: Advisory Panel; Self; AstraZeneca. Speaker’s Bureau; Self; Dexcom, Inc., Medtronic, Roche Diabetes Care, Sanofi, Ypsomed AG. P. von Blanckenburg: None. W. Keuthage: Advisory Panel; Self; Deutschland GmbH, Novo Nordisk A/S, Roche Diabetes Care. Board Member; Self; Abbott, Berlin-Chemie AG. R. Ziegler: Advisory Panel; Self; Abbott, Lilly Diabetes, Novo Nordisk A/S, Roche Diabetes Care. Consultant; Self; Novo Nordisk A/S, Roche Diabetes Care. Speaker’s Bureau; Self; Abbott, Dexcom, Inc., Novo Nordisk A/S, Roche Diabetes Care. E. Martin: None. M. Holder: None. D. Deiss: Advisory Panel; Self; Abbott, Roche Diabetes Care. Consultant; Self; Senseonics. G. Buchal: None. L. van den Boom: Advisory Panel; Self; Medtronic. K. Lange: Consultant; Self; Abbott, Dexcom, Inc., Medtronic.

Funding

Dexcom, Inc.; Roche Diabetes Care; Sanofi; Menarini Group; Kirchheim Verlag; Medtronic